KEGG   DRUG: Delandistrogene moxeparvovec
Entry
D12633                      Drug                                   
Name
Delandistrogene moxeparvovec (USAN/INN);
Delandistrogene moxeparvovec-rokl;
Elevidys (TN)
Product
ELEVIDYS (Sarepta Therapeutics)
Remark
Therapeutic category: 1900
ATC code: M09AX15
Product: D12633<US>
Efficacy
Nervous system disease agent
  Disease
Duchenne muscular dystrophy [DS:H01963]
  Type
Gene therapy product
Comment
Recombinant adeno-associated virus AAVrh74 vector SRP-9001 MHCK7 promoter plus micro-dystrophin-specifyingTreatment of Duchenne muscular dystrophy
Target
DMD* [HSA_VAR:1756v1] [HSA:1756] [KO:K10366]
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 M MUSCULO-SKELETAL SYSTEM
  M09 OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
   M09A OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
    M09AX Other drugs for disorders of the musculo-skeletal system
     M09AX15 Delandistrogene moxeparvovec
      D12633  Delandistrogene moxeparvovec (USAN/INN) <US>
Therapeutic category of drugs in Japan [BR:br08301]
 1  Agents affecting nervous system and sensory organs
  19  Other agents affecting nervous system and sensory organs
   190  Other agents affecting nervous system and sensory organs
    1900  Other agents affecting nervous system and sensory organs
     D12633  Delandistrogene moxeparvovec (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Not elsewhere classified
  Cellular process
   Cytoskeleton
    DMD* [HSA_VAR:1756v1]
     D12633  Delandistrogene moxeparvovec (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 Cellular and gene therapy products
  D12633
New drug approvals in Japan [br08318.html]
 Cellular and gene therapy products
  D12633
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12633
Other DBs
CAS: 2305040-16-6
PubChem: 497621046
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system